Advancing Neuroscience Discovery—Raising the Bar in Analytical Speed and Precision

Protein biomarkers are critical in neuroscience research, particularly for developing therapies for neurodegenerative and neuroinflammatory diseases like Alzheimer's, multiple sclerosis (MS), and traumatic brain injury. However, early detection remains a challenge, often delaying essential clinical interventions. This case study highlights recent studies showcasing the Ella microfluidic immunoassay’s superior performance compared to other next-generation platforms. With a hands-off workflow, unmatched precision, and reliable performance across varying conditions, Ella enables more accurate detection of early-stage neurological disorders, driving advancements in diagnostics and therapeutic strategies.